Why Teva's Stock Could Crash Another 50% Post author:Sam Post published:November 7, 2017 Post category:BioPharma Teva continues to be battered by its massive debt load and struggling pipeline. Source: BioSpace You Might Also Like AstraZeneca PLC Forges $400 Million Parkinson's R&D Deal With Takeda August 28, 2017 3 Little-Known Biotechs That Could Double Overnight March 7, 2017 Why Amgen Needs an Acquisition to Keep Up with Immuno-Oncology Competitors July 9, 2017
